Main Management ETF Advisors LLC Cuts Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Main Management ETF Advisors LLC cut its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 8.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 33,464 shares of the company’s stock after selling 3,008 shares during the period. Main Management ETF Advisors LLC’s holdings in Hims & Hers Health were worth $809,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $28,000. Raleigh Capital Management Inc. boosted its holdings in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. increased its stake in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $38,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on HIMS shares. TD Cowen cut Hims & Hers Health from a “buy” rating to a “hold” rating and dropped their price target for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Piper Sandler reaffirmed a “neutral” rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Truist Financial decreased their price target on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research note on Thursday, April 10th. UBS Group reaffirmed a “mixed” rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Bank of America increased their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a report on Tuesday, April 29th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $37.67.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $64.02 on Wednesday. The company has a market capitalization of $14.33 billion, a P/E ratio of 145.50 and a beta of 1.84. The company has a 50 day simple moving average of $33.85 and a 200-day simple moving average of $32.96. Hims & Hers Health, Inc. has a 1 year low of $13.12 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $586.01 million during the quarter, compared to analysts’ expectations of $535.21 million. During the same quarter last year, the firm earned $0.05 earnings per share. The firm’s quarterly revenue was up 110.7% compared to the same quarter last year. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In related news, insider Irene Becklund sold 2,203 shares of the stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the transaction, the insider now owns 8,007 shares of the company’s stock, valued at approximately $230,441.46. This represents a 21.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the sale, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 563,973 shares of company stock worth $21,951,757. Company insiders own 13.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.